Dyslipidemia is positively associated with cervical cancer in Korea: Korean national health and nutrition examination survey 2010—2020

Several previous papers have reported that hypoxic environments induced by hypertension, Insulin like growth factor-1 (IGF-1) overexpressed by hyperinsulinemia, hyperactivity of fatty acid metabolism, stimulation of cell growth signaling factors, and formation of carcinogen by dyslipidemia contribute to tumor cell proliferation.Therefore, we hypothesized that hypertension, diabetes, and dyslipidemia are positively correlated with cervical cancer; the purpose of this study was to evaluate this correlation. We included 25,055 participants from the Korean National Health and Nutrition Examination Survey between 2010 and 2020. The participants were divided into the non-cervical cancer and cervical cancer groups. For comparisons between the two groups, continuous variables were analyzed using Student’s t-test, and categorical variables were analyzed using the chi-squared test or Fisher’s exact test. The odds ratios (OR) in the non-cervical cancer group, and 311 females were included in the cervical cancer group. In the cervical cancer group, dyslipidemia had an adjusted OR (AOR) of 2.88 compared with that of the non-cervical cancer group (AOR: 2.88, confidence interval (CI): 1.785–4.654, p < 0.001) after adjusting for confounding variables such as age, education level, waist circumference, body mass index (BMI), and number of pregnancies in the multivariate logistic regression analysis. Among the three major chronic diseases, dyslipidemia was positively correlated with cervical cancer. Therefore, Encouraging gynecologists to get proper treatment for dyslipidemia in gynecological patients with dyslipidemia is believed to help lower the potential risk of cervical cancer in the future.

Cervical cancer; Dyslipidemia; Korean females; Chronic diseases

[1] Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999–2017: Korea central cancer registry. Obstetrics and Gynecology Science. 2021; 64: 444–453.

[2] Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in republic of Korea. 2019. Available at: https://hpvcentre.net/statistics/reports/KOR.pdf (Accessed: 31 March 2022).

[3] Davidson MH, Pulipati VP. Dyslipidemia-endocrineand metabolic disorders: msdmanual professional edition. 2022. Available at: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia (Accessed: 06 June 2023).

[4] Korea Disease Control and Prevention Agency. Korean chronic disease health statistics. 2020. Available at: https://chs.kdca.go.kr/cdhs/biz/pblcVis/details.do (Accessed: 11 May 2022).

[5] Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Medical Journal. 2005; 46: 449–455.

[6] Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology. 2005; 202: 654–662.

[7] Masur K, Vetter C, Hinz A, Tomas N, Henrish H, Niggemann B, et al. Diabetogenic glucose and insulin concentrations modulate transcriptom and protein levels involved in tumour cell migration, adhesion and proliferation. British Journal of Cancer. 2011; 104: 345–352.

[8] Bárdos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochimica et Biophysica Acta—Reviews on Cancer. 2005; 1755: 107–120.

[9] Cowey S, Hardy RW. The metabolic syndrome a high-risk state for cancer? The American Journal of Pathology. 2006; 169: 1505–1522.

[10] Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. Journal of Cellular Physiology. 2019; 234: 5683–5699.

[11] Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the united states: a study in the seer-medicare linked database. Cancer Epidemiology, Biomarkers & Prevention. 2015; 24: 261–267.

[12] Penaranda EK, Shokar N, Ortiz M. Relationship between metabolic syndrome and history of cervical cancer among a US national population. ISRN Oncology. 2013; 2013: 840964.

[13] Ulmer H, Bjørge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (me-can). Gynecologic Oncology. 2012; 125: 330–335.

[14] Oh HY, Kim MK, Seo S, Lee J. Association of combined tobacco smoking and oral contraceptive use with cervical intraepithelial neoplasia 2 or 3 in Korean women. Journal of Epidemiology. 2016; 26: 22–29.

[15] International Collaboration of Epidemiological Studies of Cervical Cancer; Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. The Lancet. 2007; 370: 1609–1621.

[16] Rinaldi S, Plummer M, Biessy C, Castellsague X, Overvad K, Kjaer SK, et al. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiology, Biomarkers & Prevention. 2011; 20: 2532–2540.

[17] Roura E, Travier N, Waterboer T, Sanjose SD, Bosch FX, Pawlita M, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLOS ONE. 2016; 11: e0147029.

[18] Kim J, Kim BK, Lee CH, Seo SS, Park S, Roh J. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. International Journal of Gynecological Cancer. 2012; 22: 1570–1576.

[19] Kim J, Song S, Jin C, Lee J, Lee N, Lee K. Factors affecting the clearance of high-risk human papillomavirus infection and the progression of cervical intraepithelial neoplasia. Journal of International Medical Research. 2012; 40: 486–496.

[20] Castle PE. How does tobacco smoke contribute to cervical carcinogenesis? Journal of Virology. 2008; 82: 6084–6086.

[21] National Statistical Office National Policy Monitoring Index. Korean women’s smoking levels analysis by statistics Korea. 2022. Available at: https://www.index.go.kr/unity/potal/main/EachDtlPageDetail.do?idx_cd=2771 (Accessed: 16 May 2022).

[22] Centers for Disease Control and Prevention. Current cigarette smoking among adults in the United States. 2022. Available at: https://www.cdc.gov/tobacco/data_statistics/fact_ sheets/adult_data/cig_smoking/index.htm (Accessed: 16 May 2022).

[23] Kaelin WG Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. Journal of the American Society of Nephrology. 2003; 14: 2703-2711.

[24] Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, et al. Hypertension, diuretics and breast cancer risk. Journal of Human Hypertension. 2006; 20: 727–732.

[25] Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. European Urology. 2019; 75: 74–84.

[26] Lindkvist B, Johansen D, Stocks T, Concin H, Bjørge T, Almquist M, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the me-can project. BMC Cancer. 2014; 14: 103.

[27] Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012; 59: 802–810.

[28] Christakoudi S, Kakourou A, Markozannes G, Tzoulaki I, Weiderpass E, Brennan P, et al. Blood pressure and risk of cancer in the European prospective investigation into cancer and nutrition. International Journal of Cancer. 2020; 146: 2680–2693.

[29] Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiology, Biomarkers & Prevention. 1997; 6: 863–873.

[30] Ursin G, Pike MC, Preston-Martin S, d’Ablaing G 3rd, Peters RK. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States). Cancer Causes & Control. 1996; 7: 391–401.

[31] Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293: 194–202.

[32] Zendehdel K, Nyrén O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. Journal of the National Cancer Institute. 2003; 95: 1797–1800.

[33] Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer. 2009; 101: 1202–1206.

[34] Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian X, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Medical Oncology. 2015; 32: 391.

[35] Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications. 2009; 385: 454–459.

[36] Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, et al. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget. 2017; 8: 11600–11613.

[37] Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. Journal of Translational Medicine. 2015; 13: 146.

[38] Papaevangelou E, Almeida GS, Box C, deSouza NM, Chung Y. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. International Journal of Cancer. 2018; 143: 992–1002.

[39] Mehta N, Hordines J, Sykes D, Doerr RJ, Cohen SA. Low density lipoproteins and lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clinical & Experimental Metastasis. 1998; 16: 587–594.

[40] Wang SF, Chou YC, Mazumder N, Kao FJ, Nagy LD, Guengerich FP, et al. 7-ketocholesterol induces p-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Biochemical Pharmacology. 2013; 86: 548–560.

[41] Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, et al. Ezetimibe is an inhibitor of tumor angiogenesis. The American Journal of Pathology. 2009; 174: 1017–1026.